# Iterum Therapeutics plc (ITRM)

Source: https://www.quantisnow.com/company/ITRM
Generated: 2026-11-17T12:13:56.485Z

- Ticker: ITRM
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- Website: iterumtx.com

## About

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

## Latest ITRM news and filings

- 2026-03-31 11:00 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-notice-of-delisting-6477821)
- 2026-03-27 13:25 UTC [Iterum Therapeutics Announces Filing of Winding Up Petition](https://www.quantisnow.com/insight/iterum-therapeutics-announces-filing-of-winding-up-petition-6473069)
- 2026-03-27 13:21 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-bankruptcy-or-receivership-6473063)
- 2026-03-03 21:45 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-other-events-6425999)
- 2026-03-02 22:00 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-notice-of-delisting-6422627)
- 2026-02-18 22:06 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-submission-of-matters-6400201)
- 2026-02-13 21:30 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Iterum Therapeutics plc](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-iterum-therapeutics-plc-6392709)
- 2026-02-13 13:00 UTC [Iterum Therapeutics Provides Business Update](https://www.quantisnow.com/insight/iterum-therapeutics-provides-business-update-6391117)
- 2026-01-26 21:30 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Iterum Therapeutics plc](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-iterum-therapeutics-plc-6360809)
- 2026-01-02 22:15 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Iterum Therapeutics plc](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-iterum-therapeutics-plc-6332581)
- 2025-12-23 22:15 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Iterum Therapeutics plc](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-iterum-therapeutics-plc-6327178)
- 2025-12-17 13:00 UTC [Iterum Therapeutics Provides Business Update](https://www.quantisnow.com/insight/iterum-therapeutics-provides-business-update-6319122)
- 2025-12-12 22:00 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-notice-of-delisting-6314583)
- 2025-12-05 13:00 UTC [Iterum Therapeutics Provides Business Update](https://www.quantisnow.com/insight/iterum-therapeutics-provides-business-update-6304383)
- 2025-11-24 13:00 UTC [Iterum Therapeutics Provides Business Update](https://www.quantisnow.com/insight/iterum-therapeutics-provides-business-update-6291079)
- 2025-11-20 12:00 UTC [Insider Buy] [Director Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)](https://www.quantisnow.com/insight/director-dunne-michael-w-bought-2191-worth-of-ordinary-shares-6287942)
- 2025-11-14 12:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Iterum Therapeutics plc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-iterum-therapeutics-plc-6279001)
- 2025-11-14 12:15 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-results-of-operations-6278972)
- 2025-11-14 12:00 UTC [Earnings Date] [Iterum Therapeutics Reports Third Quarter 2025 Financial Results](https://www.quantisnow.com/insight/iterum-therapeutics-reports-third-quarter-2025-financial-results-6278916)
- 2025-11-07 13:00 UTC [Earnings Date] [Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025](https://www.quantisnow.com/insight/iterum-therapeutics-to-report-third-quarter-2025-financial-results-on-6267282)
- 2025-10-16 21:18 UTC [SEC Form 8-K] [SEC Form 8-K filed by Iterum Therapeutics plc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-iterum-therapeutics-plc-6236071)
- 2025-10-16 21:16 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Iterum Therapeutics plc](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-iterum-therapeutics-plc-6236065)
- 2025-10-14 12:30 UTC [Iterum Therapeutics to Present Data at IDWeek 2025](https://www.quantisnow.com/insight/iterum-therapeutics-to-present-data-at-idweek-2025-6231606)
- 2025-09-19 12:00 UTC [Iterum Therapeutics Provides Business Update](https://www.quantisnow.com/insight/iterum-therapeutics-provides-business-update-6206311)
- 2025-09-10 20:15 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-submission-of-matters-6196602)
- 2025-08-28 20:30 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-notice-of-delisting-6182658)
- 2025-08-20 12:15 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-regulation-fd-disclosure-6172907)
- 2025-08-20 12:00 UTC [Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.](https://www.quantisnow.com/insight/iterum-therapeutics-launches-orlynvah-the-first-and-only-oral-penem-6172846)
- 2025-08-12 11:00 UTC [Insider Buy] [Director Dunne Michael W. bought $10,854 worth of Ordinary Shares (15,000 units at $0.72), increasing direct ownership by 7% to 235,001 units (SEC Form 4)](https://www.quantisnow.com/insight/director-dunne-michael-w-bought-10854-worth-of-ordinary-shares-6159522)
- 2025-08-05 11:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Iterum Therapeutics plc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-iterum-therapeutics-plc-6146278)
- 2025-08-05 11:15 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-results-of-operations-6146223)
- 2025-08-05 11:00 UTC [Earnings Date] [Iterum Therapeutics Reports Second Quarter 2025 Financial Results](https://www.quantisnow.com/insight/iterum-therapeutics-reports-second-quarter-2025-financial-results-6146061)
- 2025-08-04 20:01 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-entry-into-a-6144555)
- 2025-07-29 12:00 UTC [Earnings Date] [Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025](https://www.quantisnow.com/insight/iterum-therapeutics-to-report-second-quarter-2025-financial-results-on-6135449)
- 2025-07-28 21:45 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Iterum Therapeutics plc](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-iterum-therapeutics-plc-6135061)
- 2025-07-18 21:00 UTC [SEC Form 8-K] [Iterum Therapeutics plc filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/iterum-therapeutics-plc-filed-sec-form-8-k-other-events-6125727)
- 2025-07-18 12:00 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Iterum Therapeutics plc](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-iterum-therapeutics-plc-6124952)
- 2025-07-03 20:16 UTC [SEC Form 4] [SEC Form 4 filed by Chief Commercial Officer Coyne Christine](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-commercial-officer-coyne-christine-6111035)
- 2025-07-03 20:15 UTC [SEC Form 3] [SEC Form 3 filed by new insider Coyne Christine](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-coyne-christine-6111002)
- 2025-07-02 20:30 UTC [Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/iterum-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-6108711)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ITRM
- Earnings history: https://www.quantisnow.com/earnings/ITRM
- Dividend history: https://www.quantisnow.com/dividends/ITRM
- Insider transactions: https://www.quantisnow.com/insiders/ITRM
- Options chain: https://www.quantisnow.com/options/ITRM
- SEC 8-K filings only: https://www.quantisnow.com/company/ITRM/8-k
- RSS and alerts for ITRM: https://www.quantisnow.com/docs/rss-feeds.md
